Glucose homeostasis

Animals exposed to LCS exhibited impaired glucose tolerance, decreased insulin sensitivity, elevated fasting glucose, hyperinsulinemia, and impaired GLP-1 release — effects that sometimes occurred eve

Effect: decline; fasting glucose levels 1.6-fold higher in ASP-exposed vs controls; 2.25- and 2.3-fold higher for males and females in ASP+MSG vs controls; in

Animals exposed to LCS exhibited impaired glucose tolerance, decreased insulin sensitivity, elevated fasting glucose, hyperinsulinemia, and impaired GLP-1 release — effects that sometimes occurred eve

Effect: decline; fasting glucose levels 1.6-fold higher in ASP-exposed vs controls; 2.25- and 2.3-fold higher for males and females in ASP+MSG vs controls; in

Animals exposed to LCS exhibited impaired glucose tolerance, decreased insulin sensitivity, elevated fasting glucose, hyperinsulinemia, and impaired GLP-1 release — effects that sometimes occurred eve

Effect: decline; fasting glucose levels 1.6-fold higher in ASP-exposed vs controls; 2.25- and 2.3-fold higher for males and females in ASP+MSG vs controls; in

Animals exposed to LCS exhibited impaired glucose tolerance, decreased insulin sensitivity, elevated fasting glucose, hyperinsulinemia, and impaired GLP-1 release — effects that sometimes occurred eve

Effect: decline; fasting glucose levels 1.6-fold higher in ASP-exposed vs controls; 2.25- and 2.3-fold higher for males and females in ASP+MSG vs controls; in

Animals exposed to LCS exhibited impaired glucose tolerance, decreased insulin sensitivity, elevated fasting glucose, hyperinsulinemia, and impaired GLP-1 release — effects that sometimes occurred eve

Effect: decline; fasting glucose levels 1.6-fold higher in ASP-exposed vs controls; 2.25- and 2.3-fold higher for males and females in ASP+MSG vs controls; in

Animals exposed to LCS exhibited impaired glucose tolerance, decreased insulin sensitivity, elevated fasting glucose, hyperinsulinemia, and impaired GLP-1 release — effects that sometimes occurred eve

Effect: decline; fasting glucose levels 1.6-fold higher in ASP-exposed vs controls; 2.25- and 2.3-fold higher for males and females in ASP+MSG vs controls; in

Animals exposed to LCS exhibited impaired glucose tolerance, decreased insulin sensitivity, elevated fasting glucose, hyperinsulinemia, and impaired GLP-1 release — effects that sometimes occurred eve

Effect: decline; fasting glucose levels 1.6-fold higher in ASP-exposed vs controls; 2.25- and 2.3-fold higher for males and females in ASP+MSG vs controls; in

Animals exposed to LCS exhibited impaired glucose tolerance, decreased insulin sensitivity, elevated fasting glucose, hyperinsulinemia, and impaired GLP-1 release — effects that sometimes occurred eve

Effect: decline; fasting glucose levels 1.6-fold higher in ASP-exposed vs controls; 2.25- and 2.3-fold higher for males and females in ASP+MSG vs controls; in

Animals exposed to LCS exhibited impaired glucose tolerance, decreased insulin sensitivity, elevated fasting glucose, hyperinsulinemia, and impaired GLP-1 release — effects that sometimes occurred eve

Effect: decline; fasting glucose levels 1.6-fold higher in ASP-exposed vs controls; 2.25- and 2.3-fold higher for males and females in ASP+MSG vs controls; in

Animals exposed to LCS exhibited impaired glucose tolerance, decreased insulin sensitivity, elevated fasting glucose, hyperinsulinemia, and impaired GLP-1 release — effects that sometimes occurred eve

Effect: decline; fasting glucose levels 1.6-fold higher in ASP-exposed vs controls; 2.25- and 2.3-fold higher for males and females in ASP+MSG vs controls; in

Animals exposed to LCS exhibited impaired glucose tolerance, decreased insulin sensitivity, elevated fasting glucose, hyperinsulinemia, and impaired GLP-1 release — effects that sometimes occurred eve

Effect: decline; fasting glucose levels 1.6-fold higher in ASP-exposed vs controls; 2.25- and 2.3-fold higher for males and females in ASP+MSG vs controls; in

Animals exposed to LCS exhibited impaired glucose tolerance, decreased insulin sensitivity, elevated fasting glucose, hyperinsulinemia, and impaired GLP-1 release — effects that sometimes occurred eve

Effect: decline; fasting glucose levels 1.6-fold higher in ASP-exposed vs controls; 2.25- and 2.3-fold higher for males and females in ASP+MSG vs controls; in

Animals exposed to LCS exhibited impaired glucose tolerance, decreased insulin sensitivity, elevated fasting glucose, hyperinsulinemia, and impaired GLP-1 release — effects that sometimes occurred eve

Effect: decline; fasting glucose levels 1.6-fold higher in ASP-exposed vs controls; 2.25- and 2.3-fold higher for males and females in ASP+MSG vs controls; in

Animals exposed to LCS exhibited impaired glucose tolerance, decreased insulin sensitivity, elevated fasting glucose, hyperinsulinemia, and impaired GLP-1 release — effects that sometimes occurred eve

Effect: decline; fasting glucose levels 1.6-fold higher in ASP-exposed vs controls; 2.25- and 2.3-fold higher for males and females in ASP+MSG vs controls; in

Animals exposed to LCS exhibited impaired glucose tolerance, decreased insulin sensitivity, elevated fasting glucose, hyperinsulinemia, and impaired GLP-1 release — effects that sometimes occurred eve

Effect: decline; fasting glucose levels 1.6-fold higher in ASP-exposed vs controls; 2.25- and 2.3-fold higher for males and females in ASP+MSG vs controls; in

Animals exposed to LCS exhibited impaired glucose tolerance, decreased insulin sensitivity, elevated fasting glucose, hyperinsulinemia, and impaired GLP-1 release — effects that sometimes occurred eve

Effect: decline; fasting glucose levels 1.6-fold higher in ASP-exposed vs controls; 2.25- and 2.3-fold higher for males and females in ASP+MSG vs controls; in

Animals exposed to LCS exhibited impaired glucose tolerance, decreased insulin sensitivity, elevated fasting glucose, hyperinsulinemia, and impaired GLP-1 release — effects that sometimes occurred eve

Effect: decline; fasting glucose levels 1.6-fold higher in ASP-exposed vs controls; 2.25- and 2.3-fold higher for males and females in ASP+MSG vs controls; in

Animals exposed to LCS exhibited impaired glucose tolerance, decreased insulin sensitivity, elevated fasting glucose, hyperinsulinemia, and impaired GLP-1 release — effects that sometimes occurred eve

Effect: decline; fasting glucose levels 1.6-fold higher in ASP-exposed vs controls; 2.25- and 2.3-fold higher for males and females in ASP+MSG vs controls; in

Animals exposed to LCS exhibited impaired glucose tolerance, decreased insulin sensitivity, elevated fasting glucose, hyperinsulinemia, and impaired GLP-1 release — effects that sometimes occurred eve

Effect: decline; fasting glucose levels 1.6-fold higher in ASP-exposed vs controls; 2.25- and 2.3-fold higher for males and females in ASP+MSG vs controls; in

Animals exposed to LCS exhibited impaired glucose tolerance, decreased insulin sensitivity, elevated fasting glucose, hyperinsulinemia, and impaired GLP-1 release — effects that sometimes occurred eve

Effect: decline; fasting glucose levels 1.6-fold higher in ASP-exposed vs controls; 2.25- and 2.3-fold higher for males and females in ASP+MSG vs controls; in

Animals exposed to LCS exhibited impaired glucose tolerance, decreased insulin sensitivity, elevated fasting glucose, hyperinsulinemia, and impaired GLP-1 release — effects that sometimes occurred eve

Effect: decline; fasting glucose levels 1.6-fold higher in ASP-exposed vs controls; 2.25- and 2.3-fold higher for males and females in ASP+MSG vs controls; in

Animals exposed to LCS exhibited impaired glucose tolerance, decreased insulin sensitivity, elevated fasting glucose, hyperinsulinemia, and impaired GLP-1 release — effects that sometimes occurred eve

Effect: decline; fasting glucose levels 1.6-fold higher in ASP-exposed vs controls; 2.25- and 2.3-fold higher for males and females in ASP+MSG vs controls; in

Animals exposed to LCS exhibited impaired glucose tolerance, decreased insulin sensitivity, elevated fasting glucose, hyperinsulinemia, and impaired GLP-1 release — effects that sometimes occurred eve

Effect: decline; fasting glucose levels 1.6-fold higher in ASP-exposed vs controls; 2.25- and 2.3-fold higher for males and females in ASP+MSG vs controls; in

Animals exposed to LCS exhibited impaired glucose tolerance, decreased insulin sensitivity, elevated fasting glucose, hyperinsulinemia, and impaired GLP-1 release — effects that sometimes occurred eve

Effect: decline; fasting glucose levels 1.6-fold higher in ASP-exposed vs controls; 2.25- and 2.3-fold higher for males and females in ASP+MSG vs controls; in

Animals exposed to LCS exhibited impaired glucose tolerance, decreased insulin sensitivity, elevated fasting glucose, hyperinsulinemia, and impaired GLP-1 release — effects that sometimes occurred eve

Effect: decline; fasting glucose levels 1.6-fold higher in ASP-exposed vs controls; 2.25- and 2.3-fold higher for males and females in ASP+MSG vs controls; in

Animals exposed to LCS exhibited impaired glucose tolerance, decreased insulin sensitivity, elevated fasting glucose, hyperinsulinemia, and impaired GLP-1 release — effects that sometimes occurred eve

Effect: decline; fasting glucose levels 1.6-fold higher in ASP-exposed vs controls; 2.25- and 2.3-fold higher for males and females in ASP+MSG vs controls; in

Animals exposed to LCS exhibited impaired glucose tolerance, decreased insulin sensitivity, elevated fasting glucose, hyperinsulinemia, and impaired GLP-1 release — effects that sometimes occurred eve

Effect: decline; fasting glucose levels 1.6-fold higher in ASP-exposed vs controls; 2.25- and 2.3-fold higher for males and females in ASP+MSG vs controls; in